A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

• Status: Active, not recruiting
• Trial end date: 2020-10-23
• Target enrollment: 0
• Participant gender: All

Summary

A Study assessing the drug levels and drug effects of variable doses of BMS-986322 in Healthy Participants compared to a placebo. The study also assesses how BMS-986322 affects the body with food and its acidity levels.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Famotidine

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Healthy Participant, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations

• Body mass index (BMI) of 18.0 kg/m^2 to 32.0 kg/m^2, inclusive, and body weight ≥ 50 kg, at screening

• Women and men must agree to follow methods of contraception.

Exclusion Criteria:

• Any significant acute or chronic medical illness

• History of recent infection

• History of allergy to BMS-986322 or other compounds

Other protocol-defined inclusion/exclusion criteria could apply.